Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence

IntroductionObesity affects over 650 million adults worldwide and is a major risk factor for cardiovascular diseases and type 2 diabetes. Among those affected are patients treated with antipsychotics, such as clozapine and olanzapine, which often lead to significant weight gain, increasing the risk...

Full description

Saved in:
Bibliographic Details
Published in:Journal of education, health and sport health and sport, 2024-12, Vol.75, p.56672
Main Authors: Gniaź, Natalia, Górska, Aleksandra, Grela, Wiktor, Niewiadomska, Jagoda, Furtak, Daria, Tulej, Dawid, Głogowska, Paulina, Dziedzic, Alicja, Marciniuk, Dominika, Marko, Natalia
Format: Article
Language:English
Subjects:
adverse effect
antipsychotic-induced weight gain
clozapine
GLP-1 receptors agonist
obesity
olanzapine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionObesity affects over 650 million adults worldwide and is a major risk factor for cardiovascular diseases and type 2 diabetes. Among those affected are patients treated with antipsychotics, such as clozapine and olanzapine, which often lead to significant weight gain, increasing the risk of metabolic syndrome. Recent advances with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and liraglutide, show promise in addressing antipsychotic-induced obesity by reducing weight and improving metabolic health. PurposeThe aim of this review is to present an overview of the current state of knowledge regarding the efficacy of GLP-1 RAs in the treatment of antipsychotic-induced obesity. Materials and methodsThis review is based on both original research studies and review articles identified through a comprehensive search of the PubMed database, using the following search terms: obesity, antipsychotic-induced weight gain, clozapine, olanzapine, adverse effect, GLP-1 receptors agonist.  Description of the state of knowledgeGLP-1 RAs significantly reduce body weight and adipose tissue by suppressing appetite, particularly for high-fat foods. Clinical trials show improvements in lipid profiles, blood pressure, and inflammation, contributing to better metabolic health. However, their long-term effects, especially with different antipsychotics, remain insufficiently studied. ConclusionsGLP-1 RAs show significant potential for managing antipsychotic-induced obesity, but further research is needed to assess long-term efficacy and safety in this population.
ISSN:2391-8306
2391-8306
DOI:10.12775/JEHS.2024.75.56672